Serum Parathyroid Hormone Responses to Vitamin D Supplementation in Overweight/Obese Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hyperthyroidism 1 endocrinologydiseases
metabolic syndrome 1 endocrinologydiseases
obesity 6 endocrinologydiseases
osteoporosis 1 endocrinologydiseases
secondary hyperparathyroidism 2 endocrinologydiseases
vascular calcification 1 endocrinologydiseases
cholecalciferol 1 endocrinologydiseasesdrugs
hyperparathyroidism 3 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cholecalciferol 29410 thoroughly investigated in future studies including the role of different formulations of vitamin D and cholecalciferol absorption. The meta-analysis showed that lower doses of vitamin D along with calcium can also significantly
Select Disease Character Offset Disease Term Instance
hyperparathyroidism 739 date (collection): 3/2017AbstractObesity is often associated with vitamin D deficiency and secondary hyperparathyroidism . Vitamin D supplementation typically leads to the reductions in serum parathyroid hormone (PTH) levels,
hyperparathyroidism 3327 obesity, such as cardiovascular disease, certain cancers, hypertension, osteoporosis, and secondary hyperparathyroidism [[2],[3],[4],[5]]. The synthesis and secretion of parathyroid hormone (PTH) is higher in those with
hyperparathyroidism 19500 commonly coincide with obesity [[4],[6]]. Vitamin D supplementation is used as a clinical treatment for hyperparathyroidism in addition to treating vitamin D deficiency caused by a multiple diseases and medications, although
hyperthyroidism 3953 impact on bone density [[4],[6]]. Low dietary calcium, skeletal muscle wasting, primary or secondary hyperthyroidism , chronic kidney disease (CKD), or inadequate vitamin D status may be independent contributors to high
metabolic syndrome 24159 poor CVD outcomes [[45],[47]]. The relationship of low serum 25OHD levels and insulin resistance and metabolic syndrome has been more consistently reported [[48],[49]], although prospective studies do not always suggest
obesity 3227 professional organizations [[3]]. Vitamin D deficiency is associated with many of the same health risks as obesity , such as cardiovascular disease, certain cancers, hypertension, osteoporosis, and secondary hyperparathyroidism
obesity 4165 high serum PTH concentrations [[4]].Alterations in the vitamin D endocrine system often occur with obesity [[7],[8],[9],[10],[11]]. Increased adiposity is reported to be positively associated with serum PTH
obesity 7586 narrowed down using the following key terms: “vitamin D supplementation and parathyroid hormone and obesity ”, “vitamin D supplementation and parathyroid hormone and obese”, and “vitamin D supplementation
obesity 19419 concentrations of serum PTH are associated with numerous adverse health outcomes and commonly coincide with obesity [[4],[6]]. Vitamin D supplementation is used as a clinical treatment for hyperparathyroidism in addition
obesity 22717 explain the relationship between PTH and cardiovascular disease.Vitamin D metabolism is altered in obesity , evidenced by low serum 25OHD levels. The proposed mechanisms include a lack of sun exposure, modified
obesity 23768 the morbidly obese population [[44]]. Understanding the mechanism(s) behind vitamin D metabolism in obesity may help individualize the treatment of vitamin D deficiency and PTH suppression. The health outcomes
osteoporosis 3299 of the same health risks as obesity, such as cardiovascular disease, certain cancers, hypertension, osteoporosis , and secondary hyperparathyroidism [[2],[3],[4],[5]]. The synthesis and secretion of parathyroid hormone
secondary hyperparathyroidism 729 3/2017Publication date (collection): 3/2017AbstractObesity is often associated with vitamin D deficiency and secondary hyperparathyroidism . Vitamin D supplementation typically leads to the reductions in serum parathyroid hormone (PTH) levels,
secondary hyperparathyroidism 3317 risks as obesity, such as cardiovascular disease, certain cancers, hypertension, osteoporosis, and secondary hyperparathyroidism [[2],[3],[4],[5]]. The synthesis and secretion of parathyroid hormone (PTH) is higher in those with
vascular calcification 5037 be due to the up-regulation of calcium-sensing receptors on the parathyroid gland, thus facilitating vascular calcification and impairing function of vascular cells [[12]]. Vitamin D supplementation can also suppress serum PTH

You must be authorized to submit a review.